Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

Core Insights - Monopar Therapeutics Inc. announced that its abstract on the long-term neurological benefits of ALXN1840 in Wilson disease patients has been selected for both oral and poster presentations at the 150th American Neurological Association Annual Meeting [1][2] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs [3] Presentation Details - The abstract titled "Long-term sustained improvement of neurological symptoms in Wilson disease patients on tiomolybdate choline" has been designated as an Abstract of Distinction by the ANA [2] - The poster presentation is scheduled for September 14, 2025, and the oral presentation for September 15, 2025 [5]